SCHEMBL5125728

SCHEMBL5125728

O=C(Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1cc(Cl)ccc1NS(=O)(=O)c1ccc(Cl)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC10A6 Q3KNW5 3/20 0.61
▸ SLC10A2 Q12908 2/20 0.61
▸ SLC10A1 Q14973 2/20 0.61
▸ TMPRSS4 Q9NRS4 6/20 0.61
▸ P2RX1 P51575 5/20 0.61
▸ P2RX4 Q99571 5/20 0.61
▸ P2RX7 Q99572 5/20 0.61
▸ MEN1 O00255 2/20 0.61
▸ KMT2A Q03164 2/20 0.61
▸ IKBKB O14920 1/20 0.61
▸ CHUK O15111 1/20 0.61
▸ KDR P35968 1/20 0.61
▸ FLT3 P36888 1/20 0.61
▸ MYLK Q15746 1/20 0.61
▸ MAP4K5 Q9Y4K4 1/20 0.61
▸ CCR9 P51686 1/20 0.59
▸ SLC20A2 Q08357 1/20 0.58
▸ SLC20A1 Q8WUM9 1/20 0.58
▸ GPR27 Q9NS67 2/20 0.54
▸ KDM1A O60341 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5115424 0.90 SLC20A2 (0.66) SLC10A6SLC10A2SLC10A1TMPRSS4P2RX1
SCHEMBL6754585 0.85 SLC10A6 (0.81) SLC10A6SLC10A2SLC10A1P2RX1MEN1
SCHEMBL6861353 0.84 CCR9 (0.62) SLC10A6SLC10A2SLC10A1TMPRSS4P2RX1
SCHEMBL5119313 0.84 SLC10A6 (0.64) SLC10A6SLC10A2SLC10A1MEN1KMT2A
SCHEMBL492037 0.83 CCR9 (0.53) SLC10A6SLC10A2SLC10A1TMPRSS4KMT2A
SCHEMBL491625 0.82 SLC10A6 (0.72) SLC10A6SLC10A2SLC10A1MEN1KMT2A
SCHEMBL5117189 0.82 SLC10A6 (0.72) SLC10A6SLC10A2SLC10A1TMPRSS4P2RX1
SCHEMBL5118300 0.82 SLC10A6 (0.68) SLC10A6SLC10A2SLC10A1CCR9SLC20A2
SCHEMBL5126827 0.81 KMT2A (0.61) SLC10A6SLC10A2SLC10A1TMPRSS4P2RX1
SCHEMBL5119995 0.81 RXFP1 (0.70) MEN1KMT2ASLC20A2SLC20A1GPR27

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7351703-B2 Sulfonylamino carboxylic acid N-arylamides as guanylate cyclase activators SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-04-01 — — US disclosed
EP-1095015-B1 SULFONYLAMINO CARBOXYLIC ACID N-ARYLAMIDES AS GUANYLATE CYCLASE ACTIVATORS AVENTIS PHARMA GMBH (DE) 2005-06-01 — — EP disclosed
US-20050080073-A1 Sulfonylaminocarboxiylic acid N-arylamides as guanylate cyclase activators AVENTIS PHARMA DEUTSCHLAND GMBH 2005-04-14 — — US disclosed
US-6809089-B2 FOR THERAPY AND PROPHYLAXIS OF CARDIOVASCULAR DISORDERS SUCH AS HIGH BLOOD PRESSURE, ANGINA PECTORIS, CARDIAC INSUFFICIENCY, THROMBOSES OR ATHEROSCLEROSIS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-10-26 — — US disclosed
US-20030171352-A1 Sulfonylaminocarboxylic acid N-arylamides as guanylate cyclase activators AVENTIS PHARMA DEUTSCHLAND GMBH 2003-09-11 — — US disclosed
US-6548547-B1 Cardiovascular disorders; hypotensive agents, antiasthmatics, cognition activators AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2003-04-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080073-A1 Sulfonylaminocarboxiylic acid N-arylamides as guanylate cyclase activators GUCY1A1, GUCY1B1, GUCY1A2 SLC10A6 2987/4885SLC10A2 1391/4885SLC10A1 1242/4885
US-20030171352-A1 Sulfonylaminocarboxylic acid N-arylamides as guanylate cyclase activators GUCY1A1, GUCY1B1, GUCY1B2 SLC10A6 3299/4885SLC10A2 1534/4885SLC10A1 1366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback